Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far
Compared to adenocarcinoma, fewer effective treatment options are available for advanced or metastatic squamous cell carcinoma (SCC) of the lung. Afatinib is an orally administered, irreversible EGFR antagonist. As a second-generation tyrosine kinase inhibitor, it has been applied in the treatment o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888861/ |